 Huntingtons disease HD is autosomal dominant neurodegenerative disease, starting in average with high variability in the fourth decade. The disease progression is classically characterized by a cognitive deterioration cortical-frontal dementia, motor disorders associating chorea, dystonia and bradykinesia, psychiatric disturbances combining depression and irritability and metabolic disorder cachexia. The disease is fatal within 15 to 20 years in most patients. HD has no cure. Neuroleptics are the main drug used and the only to demonstrate its efficacy on chorea in clinical trials. But neuroleptics have also beneficial and adverse effects on other disease characteristics motor, psychiatric, cognitive or metabolic. Their profile between beneficial and adverse effects could be different according the neuroleptics and their classification. The aim of this study is to compare beneficial and adverse effects of 3 different neuroleptics in HD. 